Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib

被引：0

作者：

Fidler, David ^{[1
]}

Gelmon, Karen A. ^{[1
]}

Simmons, Christine ^{[1
]}

机构：

[1] Univ British Columbia, BC Canc, Vancouver, BC V5Z 4E6, Canada

来源：

FUTURE ONCOLOGY | 2025年

关键词：

Tucatinib; trastuzumab; capecitabine; T-DXd; HER2-positive metastatic breast cancer; tyrosine kinase inhibitor; HER2CLIMB trial; brain metastases; LAPATINIB PLUS CAPECITABINE; PHASE-II TRIAL; BRAIN METASTASES; TRASTUZUMAB DERUXTECAN; COMBINATION; MULTICENTER; PERTUZUMAB; INHIBITOR; DOCETAXEL; EMTANSINE;

D O I：

10.1080/14796694.2025.2529151

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it improves survival for heavily pretreated patients, including patients with brain metastases. Its efficacy was demonstrated in the HER2CLIMB trial and it stands as an optimal choice for patients with brain metastases, a patient population who have historically been excluded from clinical trials. Tucatinib is orally administered and has a manageable safety profile. Common adverse events include diarrhea, nausea, fatigue, and liver enzyme elevations, which are typically manageable with dose modifications and supportive care. With strong clinical efficacy and widespread approval since 2020, tucatinib remains an important treatment option for patients with HER2-positive metastatic breast cancer.

引用

页数：11

共 78 条

[1] Real-world clinical outcomes in patients with HER2+metastatic breast cancer receiving tucatinib therapy after 2 or more prior HER2-directed therapies [J].

Anders, C. ;

Neuberger, E. ;

Bartley, K. ;

Pittner, B. ;

Sow, A. ;

Wang, S. ;

Kaufman, P. .

EUROPEAN JOURNAL OF CANCER, 2024, 200 :17-18

[2]

[Anonymous], 2020, FDA approves tucatinib for patients with HER2-positive metastatic breast cancer

[3]

[Anonymous], 2023, Tukysa® (Tucatinib) reimbursed in Ontario, Manitoba and Saskatchewan for the treatment of patients with advanced or metastatic HER2-positive breast cancer

[4]

[Anonymous], 2025, Tukysa® (tucatinib) clinical pharmacology

[5]

[Anonymous], 2019, FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

[6] Current and future burden of breast cancer: Global statistics for 2020 and 2040 [J].

Arnold, Melina ;

Morgan, Eileen ;

Rumgay, Harriet ;

Mafra, Allini ;

Singh, Deependra ;

Laversanne, Mathieu ;

Vignat, Jerome ;

Gralow, Julie R. ;

Cardoso, Fatima ;

Siesling, Sabine ;

Soerjomataram, Isabelle .

BREAST, 2022, 66 :15-23

[7] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[8] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial [J].

Bartsch, Rupert ;

Berghoff, Anna Sophie ;

Furtner, Julia ;

Marhold, Maximilian ;

Bergen, Elisabeth Sophie ;

Roider-Schur, Sophie ;

Starzer, Angelika Martina ;

Forstner, Heidrun ;

Rottenmanner, Beate ;

Dieckmann, Karin ;

Bago-Horvath, Zsuzsanna ;

Haslacher, Helmuth ;

Widhalm, Georg ;

Ilhan-Mutlu, Aysegul ;

Minichsdorfer, Christoph ;

Fuereder, Thorsten ;

Szekeres, Thomas ;

Oehler, Leopold ;

Gruenberger, Birgit ;

Singer, Christian F. ;

Weltermann, Ansgar ;

Puhr, Rainer ;

Preusser, Matthias .

NATURE MEDICINE, 2022, 28 (09) :1840-+

[9] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress [J].

Catenacci, Daniel V. T. ;

Strickler, John H. ;

Nakamura, Yoshiaki ;

Shitara, Kohei ;

Janjigian, Yelena Y. ;

Barzi, Afsaneh ;

Bekaii-Saab, Tanios S. ;

Lenz, Heinz-Josef ;

Chung, Hyun Cheol Cheol ;

Tabernero, Josep ;

Yoshino, Takayuki ;

Siena, Salvatore ;

Mayor, Joal Garrido ;

Palanca-Wessels, Maria Corinna ;

Xie, Diqiong ;

Marshall, John .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[10] Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? [J].

Chien, Amy Jo ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) :3089-+

← 1 2 3 4 5 6 7 8 →